Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
Cancer Investigation|August 7, 2003
The androgen receptor: structure, mutations, and antiandrogensSamit Hirawat, Daniel R Budman, Willi KreisAnti-Cancer Drugs|November 20, 2002
Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitroDaniel R Budman, Anthony Calabro, Willi KreisCancer Investigation|May 29, 2007
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabineSamit Hirawat, Jonathan Kolitz, Stuart M Lichtman, et al.Annals of the New York Academy of Sciences|April 5, 2013
Challenges in the clinical development of PI3K inhibitorsCristian Massacesi, Emmanuelle di Tomaso, Nathalie Fretault, et al.Seminars in Oncology|February 24, 2005
Dose and schedule as determinants of outcomes in chemotherapy for breast cancerDaniel R BudmanOncology (Williston Park, N.Y.)|November 19, 2002
New directions with capecitabine combinations in advanced breast cancerDaniel R BudmanOncology|April 29, 2006
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agentsDaniel R Budman, Anthony CalabroBreast Cancer Research and Treatment|August 2, 2002
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell linesDaniel R Budman, Anthony CalabroCancer Investigation|June 14, 2005
Review: tubulin function, action of antitubulin drugs, and new drug developmentFederico Pellegrini, Daniel R BudmanAnti-Cancer Drugs|October 1, 2004
Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111Daniel R Budman, Anthony CalabroPageof 6